Axsome Therapeutics, INC

Axsome Therapeutics announced the FDA has accepted its New Drug Application for AXS-12 (reboxetine) for treating cataplexy in narcolepsy, with a target action date of May 1, 2027.

Axsome Therapeutics has implemented a new Executive Severance and Change in Control Plan to formalize benefits for key employees.

Axsome Therapeutics stockholders approved all proposals at the 2026 Annual Meeting, including director elections and executive compensation.

Axsome Therapeutics announced the resolution of all patent litigation concerning its product SUNOSI (solriamfetol), granting generic entry rights starting in 2040.

Axsome Therapeutics reported strong Q1 2026 results with 57% YoY revenue growth, driven by AUVELITY and SUNOSI, and provided updates on its expanding CNS pipeline and new indications.

The FDA has approved Axsome Therapeutics' AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease.

Axsome Therapeutics announced its first-quarter 2026 financial results, highlighting significant revenue growth driven by its key products.

Axsome Therapeutics reported significant revenue increases and a reduced net loss for the nine months ended September 30, 2025, driven by strong product sales and new product launches.

Axsome Therapeutics reported significant revenue growth driven by its commercial products and secured a new $570 million debt facility, while continuing to advance its pipeline and manage ongoing legal and regulatory challenges.

Axsome Therapeutics announces strong Q1 2025 financial results, with total revenue increasing to $121.5 million driven by product sales and royalty revenue.

Axsome Therapeutics' Q3 2024 results show significant revenue growth driven by increased sales of Auvelity and Sunosi, alongside ongoing clinical development programs.

Axsome Therapeutics reports a net loss of $79.3 million for the second quarter of 2024, with product sales reaching $86.5 million.

Axsome Therapeutics achieved significant revenue growth in 2025, driven by commercial product sales, while advancing its robust CNS pipeline with key regulatory milestones and new acquisitions.

Axsome Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides an overview of its commercial products and development programs.

Axsome Therapeutics' 2023 10-K filing highlights commercial progress with Auvelity and Sunosi, alongside ongoing clinical development programs.

Axsome Therapeutics CEO Herriot Tabuteau executed a 10b5-1 plan transaction on July 1, 2026, involving the exercise of stock options and subsequent sale of shares.

Director Roger Jeffs sold a total of 572 shares of Axsome Therapeutics common stock to cover tax obligations related to RSU settlements.

Axsome Therapeutics Director Roger Jeffs has increased his direct ownership to 58,939 shares following the scheduled vesting of restricted stock units.

Director Mark E. Saad acquired 1,429 shares of Axsome Therapeutics following the scheduled vesting of restricted stock units.

Director Susan Mahony converted 1,429 restricted stock units and sold 600 shares to satisfy tax obligations under a pre-arranged trading plan.

Axsome Therapeutics director Mark Coleman converted 1,429 restricted stock units and sold 643 shares to satisfy tax liabilities under a Rule 10b5-1 plan.

Axsome Therapeutics has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.

Axsome Therapeutics has scheduled its 2025 Annual Meeting for June 6, 2025, and is seeking stockholder votes on director election, incentive plan approval, auditor ratification, and executive compensation.

Axsome Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 6, 2025, featuring proposals including director election, incentive plan approval, auditor ratification, and executive compensation advisory vote.

Axsome Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.

The Vanguard Group has reported a 0% beneficial ownership in Axsome Therapeutics Inc. following an internal corporate realignment.

RTW Investments, LP and Roderick Wong, M.D. have filed an amended Schedule 13G, disclosing a 3.1% beneficial ownership stake in Axsome Therapeutics, Inc.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a continued beneficial ownership of 6.0% in Axsome Therapeutics, Inc. common stock.

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a passive 8.4% beneficial ownership stake in Axsome Therapeutics, Inc. as of December 31, 2024.